AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) traded down 3.2% during trading on Thursday . The stock traded as low as $3.52 and last traded at $3.64, with a volume of 237,010 shares traded. The stock had previously closed at $3.76.

Several equities research analysts have commented on the company. Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, July 29th. Janney Montgomery Scott assumed coverage on AcelRx Pharmaceuticals in a research report on Thursday, April 14th. They issued a “neutral” rating on the stock. HC Wainwright restated a “buy” rating on shares of AcelRx Pharmaceuticals in a research report on Monday. Jefferies Group restated a “buy” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, June 10th. Finally, Seaport Global Securities upgraded AcelRx Pharmaceuticals from an “accumulate” rating to a “buy” rating in a research report on Friday, May 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $7.63.

The firm’s market cap is $161.31 million. The stock’s 50-day moving average price is $2.96 and its 200 day moving average price is $3.32.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.02. The firm earned $4.53 million during the quarter, compared to analyst estimates of $2.17 million. Equities research analysts expect that AcelRx Pharmaceuticals Inc. will post ($0.90) earnings per share for the current fiscal year.

In other news, CEO Howard B. Rosen purchased 10,206 shares of the business’s stock in a transaction on Friday, May 13th. The shares were bought at an average price of $3.26 per share, with a total value of $33,271.56. Following the completion of the transaction, the chief executive officer now directly owns 50,000 shares in the company, valued at approximately $163,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark G. Edwards purchased 15,000 shares of the business’s stock in a transaction on Thursday, May 12th. The shares were purchased at an average cost of $3.15 per share, for a total transaction of $47,250.00. Following the transaction, the director now owns 105,000 shares of the company’s stock, valued at $330,750. The disclosure for this purchase can be found here.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.